Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Feb
20
Today In Oncology
Stage II Melanoma Adjuvant Pembrolizumab and Risk of New Skin Cancers
Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo